Panoptes Pharma
Developing innovative small molecule drugs to treat eye diseases with high unmet medical need.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
$4.0m Valuation: $4.0m | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Panoptes Pharma is a privately held clinical-stage biotech company based in Vienna, Austria, specializing in the development of small molecule-based therapies for severe eye diseases that have high unmet medical needs. The company's primary focus is on creating safer and more effective alternatives to steroids for treating sight-threatening conditions. Panoptes Pharma operates in the biopharmaceutical market, targeting conditions such as uveitis and viral conjunctivitis. The business model involves advancing their key products, PaniJect and PaniDrop, to proof of concept stages, which are critical milestones in drug development. The company generates revenue through partnerships and potential future licensing deals with larger pharmaceutical companies. Panoptes Pharma serves patients suffering from severe ocular diseases, aiming to improve their quality of life through innovative treatments.
Keywords: small molecule therapies, severe eye diseases, clinical-stage biotech, uveitis, viral conjunctivitis, PaniJect, PaniDrop, biopharmaceutical market, drug development, Vienna.